Biopharmaceutical Excipients
Excipients are often overlooked. Why are they suddenly strategic?
A (Formulation Scientist - Biologics): Excipients are critical for protein stability. Monoclonal antibodies are prone to aggregation, oxidation, and deamidation. Polysorbate 80 and polysorbate 20 are the most common surfactants to prevent aggregation, but they hydrolyze over time, leading to particles. New excipients like poloxamer 188, sucrose octasulfate, and recombinant human serum albumin (without blood products) are gaining traction.
B (Quality Control - Parenteral Manufacturing): The 2022-2024 shortage of polysorbate 80 due to supply chain issues and manufacturer shutdowns was a wake-up call. Many biologics were at risk of supply disruption. Now, companies are dual-sourcing, qualifying alternative excipients (e.g., polysorbate 80 from different manufacturers or poloxamer 188), and building excipient inventories as strategic stockpiles.
C (Regulatory Affairs - CMC): Novel excipients face a high regulatory bar. The FDA has a "nonclinical safety assessment" guidance, but many new excipients are treated as new chemical entities, requiring toxicology studies that cost $1-5M. The FDA's Novel Excipient Review Pilot Program (initiated 2020, extended 2024) allows voluntary review without a drug application, but uptake has been slow. We need regulatory incentives.
D (Supply Chain Director): Excipients are not "inactive" ingredients. They are critical materials. During COVID, we had 48-hour lead times for polysorbate. Now it's 4-6 months. We're qualifying local suppliers in India and China to reduce dependence on European and US sources. The days of just-in-time excipient inventory are over. It's now just-in-case.